|
|
Drugs of Tomorrow 2001: Hypertension - The Mounting Pressures Facing New CompoundsPublished by: Datamonitor Published: May. 23, 2001 - 194 Pages Table of ContentsDrugs of Tomorrow 2001: Hypertension - The Mounting Pressures Facing New Compounds EXECUTIVE SUMMARY Scope Datamonitor insight into the hypertension market Key metrics DISEASE OVERVIEW Disease overview Definition of disease Classification of disease Patient potential Classification of pipeline products Launched products Developmental classes Clinical endpoints in disease Reduction in blood pressure Reduction in major cardiovascular events Multiple endpoints Quality of life Unmet needs in hypertension Guidelines Screening and diagnosis Compliance Patient education Side effects Patients with low renin levels Efficacy Sub-populations Reducing the pill burden on patients HYPERTENSION PIPELINE ANALYSIS Pipeline overview Pipeline analysis by class Pipeline analysis by indication Pipeline analysis by company type Licensing agreements in hypertension Potential licensing partners Pipeline analysis by individual company Pipeline analysis by region DRUG ANALYSIS Introduction CCBs Azelnidipine Watanidipine Pranidipine Semotiadil Angiotensin II receptor blockers (AIIRBs) Olmesartan ( CS 866) KT 3671 Vaso-endopeptidase inhibitors (VEPs) Omapatrilat Sampatrilat SLV 306 Endothelin receptor antagonists (ERAs) LU 135252/HMR 4005 Sitaxsentan (TBC-11252) Selective aldosterone receptor antagonists (SARAs) Eplerenone Sodium/Potassium ATPase inhibitors PST 2283 Advanced Glycosylation End-product (AGE) crosslink breakers ALT-711 Key phase I development projects GA0013 Z13752A / GW660511X TBC3711 Angiotensin Vaccine Key pre-clinical/research development projects VEP antagonists Gene therapy COMPARATIVE ANALYSIS Comparison by class Market potential FUTURE FOCUS IN HYPERTENSION Forecast summary Forecast methodology Predicting first year market share Anti-hypertensive drug class growth Individual drug growth Forecasting future growth Market drivers in hypertension Forecast overview Prospective drug launches in hypertension Breakdown by compound Breakdown by class Hypertension market forecasts Key R&D product forecasts Calcium channel blockers Angiotensin II receptor blockers Vaso-endopeptidase inhibitors Selective aldosterone receptor antagonists Endothelin receptor antagonists Long term potential of early phase compounds PST 2283 ALT-711 Second generation agents Improving compliance APPENDIX Clinical trial data bibliography Other references Forecasting methodology Forecasting drug launches for drugs in development in the hypertension area Global highest stage of development Reclassification of development phases Probability of a product progressing to launch List of tables List of figures (c) Datamonitor 2001. All Rights Reserved. AbstractDrugs of Tomorrow 2001: Hypertension provides in-depth analysis of compounds in late phase development for hypertension and an evaluation of the impact of these drugs on the market, over the period to 2007.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||